Victory Capital Management Inc. Purchases 97,200 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Victory Capital Management Inc. lifted its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 41.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 334,450 shares of the biotechnology company’s stock after purchasing an additional 97,200 shares during the period. Victory Capital Management Inc. owned 1.10% of AnaptysBio worth $4,428,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ANAB. China Universal Asset Management Co. Ltd. raised its position in AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 644 shares during the period. Point72 DIFC Ltd raised its position in AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 5,342 shares during the period. SG Americas Securities LLC raised its position in AnaptysBio by 35.0% in the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 4,231 shares during the period. Intech Investment Management LLC bought a new stake in AnaptysBio in the third quarter worth about $229,000. Finally, Janus Henderson Group PLC bought a new stake in AnaptysBio in the third quarter worth about $250,000.

AnaptysBio Trading Down 0.7 %

Shares of NASDAQ:ANAB opened at $16.73 on Friday. The company has a 50 day moving average of $16.58 and a 200 day moving average of $23.28. The stock has a market cap of $513.06 million, a P/E ratio of -2.75 and a beta of 0.02. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to analysts’ expectations of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Insider Activity at AnaptysBio

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 33.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have commented on ANAB. Wells Fargo & Company lifted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Wolfe Research started coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 price target on the stock. HC Wainwright reissued a “neutral” rating and issued a $22.00 price target on shares of AnaptysBio in a research report on Tuesday, March 4th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Truist Financial lowered their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.11.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.